questionText: To ask the Secretary of State for Health and Social Care, when he plans to expand prescribing of GLP-1 medications beyond specialist weight-management services.
answerText: National Institute for Health and Care Excellence (NICE) guidance on the first two GLP-1 medicines licensed for the treatment of obesity, namely liraglutide under various brand names and semaglutide with brand name Wegovy, restricted their use to speciali...
heading: Obesity: Drugs